8-K 1 v416883_8k.htm CURRENT REPORT

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 8-K

 

CURRENT REPORT PURSUANT

TO SECTION 13 OR 15(D) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of report (Date of earliest event reported): July 31, 2015

 

ABEONA THERAPEUTICS INC.

(Exact name of registrant as specified in its charter)

 

Delaware 0-9314 83-0221517
(State or other jurisdiction of
incorporation)
(Commission File Number) (I.R.S. Employer Identification
No.)

 

3333 Lee Parkway, Suite 600, Dallas, TX 75219
(Address of principal executive offices) (Zip Code)

 

(214) 665-9495

(Registrant’s telephone number, including area code)

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 
 

 

Item 8.01.  Other Events

 

On August 3, 2015, Abeona Therapeutics Inc. (the “Company”) issued a press release announcing that the Company had closed an upsized $15.5 million direct placement of registered common stock with institutional investors, including Soros Fund Management and Perceptive Life Science Fund, and two members of the Board of Directors. The financing is comprised of 2.83 million shares of common stock at a price of $5.50 per share.

 

A copy of the press release is furnished as Exhibit 99.1 and is incorporated by reference.

 

A copy of the “Form of” Purchase Agreement used in the financing is furnished as Exhibit 10.1 and is incorporated by reference

 

Item 9.01.  Financial Statements and Exhibits.

 

(d)  Exhibits.

 

The Company hereby furnishes the following exhibits:

 

99.1Press release dated August 3, 2015, entitled “Abeona Therapeutics Announces Closing of Upsized $15.5 Million Equity Financing with Institutional Investors and Management”
10.1Form of Purchase Agreement

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Abeona Therapeutics Inc.
  (Registrant)
     
  By: /s/ Stephen B. Thompson
  Stephen B. Thompson
  Vice President Finance

 

Date: August 3, 2015

 

 
 

  

EXHIBIT INDEX

 

Exhibit Number

 

99.1Press release dated August 3, 2015, entitled “Abeona Therapeutics Announces Closing of Upsized $15.5 Million Equity Financing with Institutional Investors and Management”
10.1Form of Purchase Agreement